Medtronic's Symplicity Spyral system shows treatment effect in hypertension study; shares up 1% premarket

May 23, 2018 7:40 AM ETMedtronic plc (MDT)MDTBy: Douglas W. House, SA News Editor
  • Medtronic (NYSE:MDT) is up 1% premarket on light volume in response to its announcement of positive preliminary results from the SPYRAL HTN-ON MED study evaluating its Symplicity Spyral renal denervation (RDN) system in patients with high blood pressure receiving anti-hypertension medications. The data were presented at EuroPCR in Paris and published in The Lancet.
  • At month 6, patients receiving treatment with Symplicity Spyral experienced an average reduction in 24-hour mean systolic (blood pressure during contraction of the heart) ambulatory blood pressure (ABPM) of 9 mm Hg, 7.4 mm Hg greater than sham control (p=0.005). The reduction in diastolic (blood pressure between heart beats) ABPM was 6.0 mm Hg, 4.1 mm Hg greater than sham control (p=0.029).
  • The positive results represent a win for the company. An earlier study, SYMPLICITY HTN-3, failed to achieve the primary endpoint.
  • Renal denervation is a minimally invasive catheter-based procedure that regulates the over-activity of nerves leading to and from the kidney which helps to lower blood pressure in patients inadequately controlled with medication.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.